Dear Editor,
Monoclonal antibodies (mAbs) blocking immune checkpoint molecules,especially programmed cell death 1 (PD-1) and its ligands programmed cell death 1 ligand 1 (PD-L1) and ligand 2 (PD-L2),are currently been investigated for treatment of various tumors [1-3].